Key Takeaways
- • Avanos Medical reports Q1 2026 earnings on May 7, potentially marking one of its final public earnings reports before American Industrial Partners' $1.3 billion all-cash acquisition closes in H2 2026.
- • Consensus expectations forecast Q1 EPS of $0.24 on revenue of $169 million, representing a sequential decline from Q4 2025's $0.29 EPS and $180.9 million revenue, though marking 71% year-over-year EPS growth.
- • American Industrial Partners agreed to acquire Avanos at $25 per share (announced mid-April 2026), representing a 72% premium to the prior day's closing price; shares currently trade at $24.66, indicating high confidence in deal closure.
- • Revenue growth expectations remain modest at under 1% year-over-year, with analyst estimates flat over the past two weeks and two months, signaling stable but unexcited market sentiment.
- • Key investor focus centers on whether management maintains full-year guidance and operational targets amid the pending sale and near-term business deceleration.
Summary
Avanos Medical, the Alpharetta, Georgia-based medical device manufacturer, will report first-quarter 2026 results on Wednesday, May 7, as the company navigates a transformative transition to private ownership. The earnings announcement arrives during a critical period for Avanos, as American Industrial Partners executes its $1.3 billion all-cash acquisition of the company—a transaction that will fundamentally reshape the company's capital structure and investor base.
Consensus analyst forecasts point to Q1 earnings of $0.24 per share on revenue of $169 million. While these figures represent a sequential pullback from the fourth quarter, when Avanos delivered $0.29 EPS on $180.9 million in revenue, the year-over-year comparison tells a different story. The expected $0.24 EPS marks a substantial 71% increase versus the same quarter one year prior, underscoring underlying operational improvement despite near-term softness. Revenue growth projections, however, remain tepid at less than 1% year-over-year growth, suggesting modest top-line momentum heading into the transaction close.
The AIP acquisition, announced in mid-April 2026, values Avanos at approximately $1.272 billion enterprise value with shareholders receiving $25 per share in all-cash consideration. This offer represented a 72% premium to the trading price immediately before announcement. The current share price of $24.66 sits just below the deal price, indicating that market participants view deal closure as highly probable and expect completion in the second half of 2026 as currently scheduled. The narrow discount reflects minimal arbitrage uncertainty, a positive signal for transaction certainty.
Analyst sentiment has stabilized with EPS and revenue estimates remaining flat over both the past week and past two months, suggesting expectations have solidified around current guidance. However, one analyst maintains a neutral rating on the stock, reflecting cautious near-term momentum. The critical question for investors at the earnings report will be management's commitment to maintaining full-year guidance and operational targets despite the pending sale, as deal uncertainty sometimes creates management hesitancy in forward commitments. The earnings print arrives at a natural inflection point—after more than a month of deal announcement clarity but before material progress toward H2 2026 closing.
Consensus analyst forecasts point to Q1 earnings of $0.24 per share on revenue of $169 million. While these figures represent a sequential pullback from the fourth quarter, when Avanos delivered $0.29 EPS on $180.9 million in revenue, the year-over-year comparison tells a different story. The expected $0.24 EPS marks a substantial 71% increase versus the same quarter one year prior, underscoring underlying operational improvement despite near-term softness. Revenue growth projections, however, remain tepid at less than 1% year-over-year growth, suggesting modest top-line momentum heading into the transaction close.
The AIP acquisition, announced in mid-April 2026, values Avanos at approximately $1.272 billion enterprise value with shareholders receiving $25 per share in all-cash consideration. This offer represented a 72% premium to the trading price immediately before announcement. The current share price of $24.66 sits just below the deal price, indicating that market participants view deal closure as highly probable and expect completion in the second half of 2026 as currently scheduled. The narrow discount reflects minimal arbitrage uncertainty, a positive signal for transaction certainty.
Analyst sentiment has stabilized with EPS and revenue estimates remaining flat over both the past week and past two months, suggesting expectations have solidified around current guidance. However, one analyst maintains a neutral rating on the stock, reflecting cautious near-term momentum. The critical question for investors at the earnings report will be management's commitment to maintaining full-year guidance and operational targets despite the pending sale, as deal uncertainty sometimes creates management hesitancy in forward commitments. The earnings print arrives at a natural inflection point—after more than a month of deal announcement clarity but before material progress toward H2 2026 closing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.